EUCTR2020-002059-38-PT进行中（未招募）1 期
A Double-Blind, Placebo-Controlled, Randomized, Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic Stroke
APTATARGETS S.L.0 个研究点目标入组 151 人开始时间: 2021年3月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 151
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age ¿18 and ¿85 years.
- •2. Informed consent obtained from subject or acceptable subject surrogate (i.e. next of kin, or legal representative).
- •3. A new focal disabling neurologic deficit consistent with acute cerebral ischemia.
- •4. Baseline NIHSS obtained prior to randomization ¿ 8 points and ¿ 25 points.
- •5. Pre-stroke mRS score of 0 - 2.
- •6. Treatable as soon as possible and at least within 6 h of symptom onset, defined as point in time when the subject was last seen well (at baseline). (Treatment start is defined as study drug administration).
- •7. Patients should be candidates to receive EVT treatment with or without i.v. rt-PA. For such patients candidates to i.v. rt-PA therapy, rt-PA should be initiated as recommended by the European Stroke Organization for the early management of patients with AIS, it means, as soon as possible and within 4.5h of stroke onset (onset time is defined as the last time when the patient was witnessed to be well at baseline), with investigator verification that the subject has received/is receiving the correct i.v. rt-PA dose for the estimated weight. Should for any reason i.v. rt-PA is prematurely halted the cause and the total administered dose will be recorded. On the other hand, once the patient is included in the study, if it is observed and documented that recanalization has occurred, the patient will continue in the trial and no protocol deviation will be recorded.
- •Neuro Imaging:
- •8. Occlusion (TICI 0 or TICI 1 flow), of the terminal internal carotid artery (TICA), M1 or M2 segments of the middle cerebral artery, suitable for mechanical thrombectomy, confirmed on CTA (CT Angiography). Tandem extra-intracranial lesions may be included.
- •9. The following imaging criteria should also be met on admission neuroimaging:
- •a) MRI criterion: volume of DWI (Diffusion-weighted Imaging) restriction ¿5 mL and ¿70 mL determined by RAPID® software OR.
- •b) CT criterion: Alberta Stroke program early CT score (ASPECTS) 6 to 10 on baseline CT AND infarct core determined on admission CTPerfusion by CBF¿30%: ¿5 mL and ¿70 mL determined by RAPID® software.
- •NOTE: ASPECTS will be stablished following the investigator criterium.
- •10. The subject has an indication and is planned to receive endovascular treatment of stroke according to the ESO Guidelines.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 121
排除标准
- •1. Subject has suffered a stroke in the past 1 year.
- •2. Occlusion (TICI 0 or TICI 1 flow) of the basilar or vertebral or posterior or anterior cerebral arteries.
- •3. Clinical symptoms suggestive of bilateral stroke or stroke in multiple territories.
- •4. Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR >3.0.
- •5. Baseline platelet count <50,000/¿L.
- •6. Baseline blood glucose of <50 mg/dL or >400 mg/dL.
- •7. Severe, sustained hypertension (systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg).
- •NOTE: If the blood pressure can be successfully reduced and maintained at an acceptable level using European Stroke Organization (ESO) guidelines recommended medication (including i.v. antihypertensive drips), the patient can be enrolled.
- •8. Serious, advanced, or terminal illness with anticipated life expectancy of less than 1 year.
- •9. Subjects with identifiable intracranial tumors.
- •10. History of life-threatening allergy (more than rash) to contrast medium.
- •11. Known renal insufficiency with creatinine ¿3 mg/dL or Glomerular Filtration Rate (GFR) <30 mL/min.
- •12. Cerebral vasculitis.
- •13. Evidence of active systemic infection.
- •14. Known current use of cocaine at time of treatment.
- •15. Patient participating in a study involving an investigational drug or device that would impact this study.
- •16. Patients that are unlikely to be available for a 90-day follow-up (e.g. no fixed home address, visitor from overseas).
- •17. Female who is pregnant or lactating or has a positive pregnancy test at time of admission.
- •Neuro Imaging:
- •18. CT or MRI evidence of hemorrhage (the presence of microbleeds is allowed).
- •19. Significant mass effect with midline shift.
- •20. Suspicion of aortic dissection presumed septic embolus, or suspicion of bacterial endocarditis
研究者
相似试验
已完成
2 期
A Double-Blind, Placebo-Controlled, Randomized, Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic StrokeStrokeDRKS00025976AptaTargets S. L.151
招募中
1 期
A Double-Blind, Placebo-Controlled, Randomized, Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic StrokeEUCTR2020-002059-38-FRAPTATARGETS S.L.151
进行中（未招募）
1 期
A Double-Blind, Placebo-Controlled, Randomized, Phase Ib/IIa Clinical Study of ApTOLL for the Treatment of Acute Ischemic StrokeEUCTR2020-002059-38-DEAPTATARGETS S.L.151
进行中（未招募）
1 期
A study to determine if A4250 is safe and can be used to treat children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2.Progressive Familial Intrahepatic Cholestasis Types 1 and 2MedDRA version: 20.0Level: PTClassification code 10076033Term: Progressive familial intrahepatic cholestasisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-002338-21-FRAlbireo AB60
进行中（未招募）
1 期
A study to determine if A4250 is safe and can be used to treat children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2.EUCTR2017-002338-21-BEAlbireo AB60